Here is a brief preview of this blast: Following JNJ's press release, Celltelligence has updated Carvykti's FDA approval for r/r MM patients having received at least 4 lines of prior therapy.
About The Author
The Celltelligence Team
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.